The Serum CA-125 Concentration Data Assists in Evaluating CT Imaging Information When Used to Differentiate Borderline Ovarian Tumor from Malignant Epithelial Ovarian Tumors

다국어 초록 (Multilingual Abstract)

Objective: We wanted to evaluate the diagnostic value of serum CA-125 concentration, when used in combination with the preoperative contrast-enhanced CT results, to differentiate borderline ovarian tumors (BOTs) from stage I malignant epithelial ovarian tumors (MEOTs).
Materials and Methods: Ninety-eight masses (46 BOTs and 52 stage I MEOTs) from 87 consecutive patients (49 with BOTs and 38 with stage I MEOTs) who had undergone preoperative contrast-enhanced computed tomography (CT) and surgical staging were evaluated retrospectively and independently by two radiologists. The preoperative serum CA-125 concentration was measured in all patients. The utility of analyzing serum CA-125 concentration in combination with the CT results was evaluated by receiver operating characteristic (ROC) curve analysis.
Results: An irregular tumor surface and lymphadenopathy were predictive of a MEOT. ROC analysis showed that the combination of CT data and the serum CA-125 level resulted in a higher diagnostic performance than did using the CT alone for differentiating BOTs from MEOTs. The areas under the curves (AUCs) without and with the use of the serum CA-125 level data were 0.67 (95% confidence interval [CI]: 0.57-0.77) and 0.78 (95% CI: 0.68-0.85), respectively, for reader 1 (p = 0.029) and 0.71 (95% CI: 0.61-0.80) and 0.81 (95% CI: 0.72-0.89), respectively, for reader 2 (p = 0.009).
Conclusion: The serum CA-125 concentration is of additional diagnostic value when used in conjunction with the CT imaging results for differentiating BOTs from MEOTs.

다국어 초록 (Multilingual Abstract)

Objective: We wanted to evaluate the diagnostic value of serum CA-125 concentration, when used in combination with the preoperative contrast-enhanced CT results, to differentiate borderline ovarian tumors (BOTs) from stage I malignant epithelial ovarian tumors (MEOTs).
Materials and Methods: Ninety-eight masses (46 BOTs and 52 stage I MEOTs) from 87 consecutive patients (49 with BOTs and 38 with stage I MEOTs) who had undergone preoperative contrast-enhanced computed tomography (CT) and surgical staging were evaluated retrospectively and independently by two radiologists. The preoperative serum CA-125 concentration was measured in all patients. The utility of analyzing serum CA-125 concentration in combination with the CT results was evaluated by receiver operating characteristic (ROC) curve analysis.
Results: An irregular tumor surface and lymphadenopathy were predictive of a MEOT. ROC analysis showed that the combination of CT data and the serum CA-125 level resulted in a higher diagnostic performance than did using the CT alone for differentiating BOTs from MEOTs. The areas under the curves (AUCs) without and with the use of the serum CA-125 level data were 0.67 (95% confidence interval [CI]: 0.57-0.77) and 0.78 (95% CI: 0.68-0.85), respectively, for reader 1 (p = 0.029) and 0.71 (95% CI: 0.61-0.80) and 0.81 (95% CI: 0.72-0.89), respectively, for reader 2 (p = 0.009).
Conclusion: The serum CA-125 concentration is of additional diagnostic value when used in conjunction with the CT imaging results for differentiating BOTs from MEOTs.

참고문헌 (Reference)

1 Yun-Jin Jang, "Variable CT Findings of Epithelial Origin Ovarian Carcinoma According to the Degree of Histologic Differentiation" 대한영상의학회 8 (8): 120-126, 2007

2 Holschneider CH, "Valvar cancer, In Berek & Novak’s gynecology, 14th ed" Lippincott Williams & Wilkins 1549-1580, 2007

3 Dobson M, "The role of computed tomography in the management of ovarian tumours of borderline malignancy" 52 : 280-283, 1997

4 Bell DA, "Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives" 35 : 934-948, 2004

5 Jacobs IJ, "Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study" 313 : 1355-1358, 1996

6 Paramasivam S, "Prognostic importance of preoperative CA- 125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study" 23 : 5938-5942, 2005

7 Brown DL, "Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the Radiology Diagnostic Oncology Group Study" 219 : 213-218, 2001

8 Rieber A, "Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings" 177 : 123-129, 2001

9 Cadron I, "Management of borderline ovarian neoplasms" 25 : 2928-2937, 2007

10 Dae Chul Jung, "MR Imaging Findings of Ovarian Cystadenofibroma and Cystadenocarcinofibroma: Clues for the Differential Diagnosis" 대한영상의학회 7 (7): 199-204, 2006

11 Buy JN, "Epithelial tumors of the ovary: CT findings and correlation with US" 178 : 811-818, 1991

12 Van Calster B, "Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125" 99 : 1706-1714, 2007

13 Choi HJ, "Contrast-enhanced CT for differentiation of ovarian metastasis from gastrointestinal tract cancer: stomach cancer versus colon cancer" 187 : 741-745, 2006

14 Tinelli R, "Conservative surgery for borderline ovarian tumors: a review" 100 : 185-191, 2006

15 Grab D, "Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography" 77 : 454-459, 2000

16 Pignata S, "Chemotherapy in epithelial ovarian cancer" 303 : 73-83, 2011

17 Zhang J, "Characterization of adnexal masses using feature analysis at contrast-enhanced helical computed tomography" 32 : 533-540, 2008

18 deSouza NM, "Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease" 184 : 999-1003, 2005

19 Jones MB, "Borderline ovarian tumors: current concepts for prognostic factors and clinical management" 49 : 517-525, 2006